Published in Curr Opin Organ Transplant on June 01, 2015
Liver biopsy. Hepatology (2009) 7.61
The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation (1984) 2.45
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
The detailed distribution of MHC Class II antigens in normal human organs. Transplantation (1984) 2.26
Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. Circulation (2009) 2.23
Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl (2011) 2.10
The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant (2011) 1.98
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Antigenic heterogeneity of vascular endothelium. Am J Pathol (1992) 1.85
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77
Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation (1985) 1.75
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation (1994) 1.71
Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl (2012) 1.67
C4d in acute rejection after liver transplantation--a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant (2006) 1.62
Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology (2010) 1.58
Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol (1987) 1.56
Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl (2006) 1.52
"Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant (2013) 1.52
Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant (2006) 1.50
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant (2015) 1.50
Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol (1988) 1.45
Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology (1990) 1.38
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol (2003) 1.32
Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation (1987) 1.31
A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology (1989) 1.30
Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant (2014) 1.29
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Antibodies in transplantation. Discov Med (2010) 1.18
Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts. Hepatology (1992) 1.18
Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation (1988) 1.16
Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol (1984) 1.11
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
What is the long-term outcome of the liver allograft? J Hepatol (2011) 1.09
Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis (1992) 1.09
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. Curr Pathobiol Rep (2013) 1.08
Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation (1993) 1.08
Immunopathological studies of orthotopic human liver allografts. Lancet (1972) 1.07
De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 1.07
Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology (2015) 1.05
Digital transplantation pathology: combining whole slide imaging, multiplex staining and automated image analysis. Am J Transplant (2011) 1.05
Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant (2011) 1.05
Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant (2012) 1.04
TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J Immunol (1997) 1.04
Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation (1990) 1.04
HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. J Immunol (2013) 1.02
Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol (2004) 0.99
Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl (2011) 0.98
Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol (2012) 0.97
Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol (2007) 0.96
HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol (1987) 0.96
Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant (2012) 0.95
Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg (1996) 0.95
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol (2012) 0.95
CIITA and Its Dual Roles in MHC Gene Transcription. Front Immunol (2013) 0.95
Regeneration-induced accelerated rejection in reduced-size liver grafts. Transplantation (1994) 0.95
Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med (2006) 0.94
Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation (1988) 0.93
Effect of microvascular rarefaction on tissue oxygen delivery in hypertension. Am J Physiol (1992) 0.93
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93
Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant (2013) 0.92
C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology (2007) 0.91
Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant (2014) 0.91
Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant (2007) 0.91
Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant (2013) 0.90
Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation (2013) 0.88
Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant (2011) 0.88
Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant (2014) 0.88
Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol (2012) 0.88
Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant (2005) 0.88
Chronic alloantibody mediated rejection. Semin Immunol (2011) 0.87
Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation (2009) 0.87
Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation (2004) 0.87
Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl (2013) 0.87
An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol (2008) 0.87
Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation (2008) 0.87
Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation (2012) 0.86
Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl (2012) 0.86
Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension. Clin Exp Immunol (1991) 0.85
The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg (1998) 0.85
Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol (1994) 0.85
Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol (2012) 0.85
Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int (2002) 0.85
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation (1990) 0.84
Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl (2014) 0.84
Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol (2013) 0.84
Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transpl (2005) 0.83
Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation (2011) 0.83
Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology (1995) 0.83
Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry. Transplant Proc (1991) 0.83
Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol (1990) 0.83
Early induction of MHC antigens in human liver grafts. An immunohistologic study. Am J Pathol (1988) 0.83
Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch (2005) 0.82
Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol (2009) 0.82
Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc (2012) 0.82
Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation (2014) 0.82
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 2.38
Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion (2006) 2.26
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant (2007) 1.30
Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med (2003) 1.28
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant (2003) 1.28
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant (2004) 1.27
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation (2006) 1.24
Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg (2009) 1.21
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol (2003) 1.17
Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology (2014) 1.16
Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol (2008) 1.16
Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol (2004) 1.12
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Interleukin-6 promoter -174 polymorphism and spontaneous preterm birth. Am J Obstet Gynecol (2003) 1.08
Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation (2008) 1.03
Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study. Crit Care (2013) 1.03
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol (2004) 1.02
Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation (2006) 1.02
The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One (2011) 1.02
Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation (2009) 1.01
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant (2006) 1.00
Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant (2005) 1.00
Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol (2007) 0.99
HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant (2004) 0.99
Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci (2007) 0.98
Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant (2009) 0.97
Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int (2008) 0.96
Renal function and genetic polymorphisms in pediatric heart transplant recipients. J Heart Lung Transplant (2012) 0.96
Tumor necrosis factor-alpha promoter gene polymorphism -308 and chorioamnionitis. Obstet Gynecol (2003) 0.95
Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol (2008) 0.95
Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol (2013) 0.95
Detection of CD8+ T cells sensitized to BK virus large T antigen in healthy volunteers and kidney transplant recipients. Hum Immunol (2006) 0.95
Functional characteristics of lymphocytes propagated from a human multivisceral allograft. Clin Transplant (1990) 0.94
Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant (2010) 0.94
Cytokine profiles in a rat model of otitis media with effusion caused by eustachian tube obstruction with and without Streptococcus pneumoniae infection. Laryngoscope (2002) 0.92
Plasma inflammatory mediators associated with bone metabolism in COPD. COPD (2010) 0.89
Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. J Heart Lung Transplant (2007) 0.89
A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics (2007) 0.89
Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant (2008) 0.89
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med (2008) 0.89
How did a patient who types for HLA-B*4403 develop antibodies that react with HLA-B*4402? Hum Immunol (2009) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
ALLOREACTIVE T LYMPHOCYTES CULTURED FROM LIVER TRANSPLANT BIOPSIES: ASSOCIATIONS OF HLA SPECIFICITY WITH CLINICOPATHOLOGICAL FINDINGS. Clin Transplant (1988) 0.87
Cytokine gene polymorphisms moderate responses to respiratory syncytial virus in adults. Hum Immunol (2003) 0.87
Role of single nucleotide polymorphisms of cytokine genes in spontaneous preterm delivery. Hum Immunol (2006) 0.87
HLA-A01-, -A03-, and -A024-binding nanomeric epitopes in polyomavirus BK large T antigen. Hum Immunol (2009) 0.87
Antibody-mediated rejection in lung transplantation: case reports. Clin Transpl (2006) 0.87
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation (2015) 0.86
Association between TNF-alpha and TGF-beta genotypes in infants and parental history of allergic rhinitis and asthma. Hum Immunol (2004) 0.86
HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation (2011) 0.86
Heart and lung transplantation in children. Lancet (2006) 0.86
Increased expression of peripheral blood leukocyte genes implicate CD14+ tissue macrophages in cellular intestine allograft rejection. Am J Pathol (2011) 0.86
Association of genetic polymorphisms and risk of late post-transplantation infection in pediatric heart recipients. J Heart Lung Transplant (2010) 0.86
Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. Mod Pathol (2008) 0.85
The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol (2002) 0.85
Antihuman leukocyte antigen–specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med (2010) 0.85
Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant (2004) 0.85
Impact of TGFbeta1 gene polymorphisms on late renal function in pediatric heart transplantation. Hum Immunol (2005) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
Gene polymorphisms impact the risk of rejection with hemodynamic compromise: a multicenter study. Transplantation (2011) 0.85
Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med (2014) 0.85
Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol (2005) 0.84
The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol (2012) 0.84
Increased lung allograft failure in patients with HLA-specific antibody. Clin Transpl (2007) 0.83
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl (2013) 0.83
Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl Immunol (2005) 0.83
Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol (2009) 0.83
Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. Pharm Res (2003) 0.83
Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation (2015) 0.82
Predicting surgical risk in patients with cirrhosis: from art to science. Gastroenterology (2007) 0.82
Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol (2009) 0.82
The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol (2009) 0.82